Loading...
NPI 1457356461 · Las Vegas, NV · Neurology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Luis Diaz is a neurology physician provider located in Las Vegas, Nevada. This profile covers 21 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Luis Diaz |
| Address | 2880 N Tenaya Way Ste 405 |
| City | Las Vegas |
| State | NV |
| ZIP | 89128 |
| Taxonomy | Neurology Physician |
| NPI Enumerated | June 16, 2005 |
| NPI Deactivated | March 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.5M |
| Medicaid | $1000 |
Medicare-dominated payer mix: this provider reports $5.5M in lifetime Medicare revenue versus $997 in lifetime Medicaid revenue, indicating Medicare is the principal payer by several orders of magnitude and the practice is effectively single-payer with respect to public programs. Medicaid activity is negligible in scale relative to Medicare.
Extreme revenue concentration in a few infusion drug codes: the precomputed top 3 Medicare codes account for 96.2% of Medicare revenue, driven primarily by J1556 (4.3M revenue, 78.9% of Medicare revenue) and J2350 (916.5K revenue, 16.6% of Medicare revenue). This concentration means the provider’s financial profile is highly dependent on a narrow set of high-cost, infusible pharmaceuticals.
Service-line implication — infusion/neurology specialty: the dominance of J1556 (immune globulin) and J2350 (ocrelizumab) combined with above-typical infusion administration codes (96365: 692 claims, $34.6K revenue; 96366: 1.4K claims, $22.2K revenue) indicates operations centered on outpatient infusion of biologic therapies and immunotherapies consistent with a neurology infusion clinic model. The presence of botulinum toxin codes (J0588, J0585) further supports specialized neurology procedural offerings beyond oral/office management.
Competitive standing on J1556 and infusion administration: J1556 ranks #1 of 46 providers nationally and is labeled an "extreme outlier," signaling national-level dominance for that specific immune globulin product. Infusion administration codes also rank very high—96366 at the 99th percentile (rank #33 of 2976) and 96365 at the 98th percentile (rank #196 of 8873)—which together indicate this provider is an outlier in infusion volume versus peers.
Other Medicare services and diagnostics are present but minor: a range of diagnostic neurophysiology codes (95886, 95910, 95909, 95911, 95819) and E/M visits (99214, 99204, 99213) appear in the top-bill list but each contributes only small shares of Medicare revenue. These codes suggest the practice mixes in diagnostic EMG/NCV and routine office care alongside its high-volume infusion business rather than relying on those services for most revenue.
Relative competitiveness for J2350 and ancillary drugs: J2350 (ocrelizumab) generates $916.5K and ranks #25 of 105 providers nationally (75th percentile), characterized as typical/unremarkable volume, which implies the provider is a meaningful regional participant for this monoclonal therapy but not dominant at the same level as for J1556. Smaller drug codes such as J0588 (incobotulinumtoxin a) and J0585 (onabotulinumtoxina) show conventional volumes and modest revenue contributions.
Medicaid footprint and local standing: Medicaid revenue is effectively immaterial at $997 lifetime, with all reported Medicaid revenue coming from 99214 (listed as 1K revenue and 100.0% of Medicaid revenue). The 99214 Medicaid rank is #1857 of 2254 in-state (17th percentile), indicating a modest in-state presence on Medicaid for office E/M visits.
Tenure and potential operational stability: the provider’s NPI was enumerated on 2005-06-16 (~21 years ago), indicating long-standing enrollment that aligns with substantial cumulative Medicare billing ($5.5M) and suggests an established practice infrastructure capable of supporting sustained, high-volume infusion services over many years.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | 77,670 | $60 | $4.3M |
| J2350 | Injection, ocrelizumab, 1 mg | 19,500 | $50 | $916.5K |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | 9,400 | $1 | $37.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 410 | $90 | $36.2K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 690 | $50 | $34.6K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 5,710 | $10 | $28.6K |
| 95886 | The provider assesses the electrical activity of a muscle in the extremity and related paraspinal areas. At the same session as a separately reportable nerve conduction study. He studies five or more… | 330 | $80 | $25K |
| 96366 | The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease. | 1,390 | $20 | $22.2K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 170 | $110 | $18.3K |
| 95910 | In this procedure, the provider performs seven or eight nerve conduction studies, a diagnostic test to evaluate the function, especially the electrical conduction ability of the motor and sensory… | 100 | $130 | $13.4K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J1556 | 1 | 10 | 75,880 | $60 | $4.3M |
| J2350 | 1 | 10 | 19,500 | $50 | $919K |
| J0585 | 18 | 30 | 5,760 | $1 | $44.8K |
| J0588 | 1 | 10 | 8,400 | $1 | $31.7K |
| 96413 | 63 | 70 | 210 | $100 | $23.7K |
| 95886 | 12 | 50 | 150 | $70 | $21.6K |
| 99214 | 612 | 3,610 | 110 | $80 | $19K |
| 95911 | 18 | 20 | 40 | $160 | $14.3K |
| 95819 | 22 | 40 | 30 | $170 | $12.8K |
| 99213 | 2,566 | 3,500 | 80 | $60 | $10K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 40 | $20 | $1K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,857 | 2,250 | 290 | $60 | $138K |
Other providers in the same ZIP code as Luis Diaz, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.